Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biota Pharmaceuticals Inc    NABI

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 5,43 M
EBIT 2017 -36,1 M
Net income 2017 -36,1 M
Debt 2017 -
Yield 2017 -
Sales 2018 5,07 M
EBIT 2018 -42,6 M
Net income 2018 -42,6 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 13,2x
Capi. / Sales2018 14,2x
Capitalization 71,9 M
More Financials
Company
Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections.Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics, currently being evaluated in ongoing Phase 2b SPIRITUS... 
Sector
Biotechnology & Medical Research
Calendar
09/27 | 08:30pmPresentation
More about the company
Surperformance© ratings of Biota Pharmaceuticals Inc
Trading Rating : Investor Rating : -
More Ratings
Latest news on BIOTA PHARMACEUTICALS INC
09/25 AVIRAGEN THERAPEUTICS : to Present at Upcoming Investor Conferences
09/14 AVIRAGEN THERAPEUTICS : Biota reports 4Q loss
09/14 Aviragen Therapeutics Reports Fourth Quarter and Fiscal Year 2016 Financial R..
09/14 Aviragen Therapeutics Announces Rescheduled Date and Time of Fourth Quarter a..
09/13 AVIRAGEN THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
09/07 AVIRAGEN THERAPEUTICS : Announces Inducement Grant for New Employees
09/07 Aviragen Therapeutics to Present at Upcoming Investor Conferences
09/07 Aviragen Therapeutics Announces Inducement Grant for New Employees
09/06 Aviragen Therapeutics Announces Schedule Change for Fourth Quarter and Fiscal..
09/01 Aviragen Therapeutics to Host Conference Call to Report Fourth Quarter and Fi..
More news
Sector news : Bio Therapeutic Drugs
02:18pDJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/26DJPfizer Throws Out Plan to Split Into Two Companies
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
More sector news : Bio Therapeutic Drugs
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus BUY
Number of Analysts 3
Average target price 4,50 $
Spread / Average Target 142%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph M. Patti President, CEO & Executive Director
Russell H. Plumb Executive Chairman
Mark P. Colonnese Chief Financial Officer & Executive Vice President
John H. Vernachio Vice President-Preclinical Development
Geoffrey F. Cox Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOTA PHARMACEUTICALS ..72
AMGEN, INC.6.90%129 863
GILEAD SCIENCES, INC.-20.33%106 391
CELGENE CORPORATION-11.23%82 402
REGENERON PHARMACEUTIC..-25.56%42 552
VERTEX PHARMACEUTICALS..-29.83%21 876
More Results